This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Basilea Pharmaceutica Ag. Active years: 2014-2015.
Company Filing History:
Years Active: 2014-2015
Title: The Innovations of Inventor Markus Heubes
Introduction
Markus Heubes, a prominent inventor based in Schopfheim, Germany, has made significant contributions to the field of pharmaceuticals through his innovative work. With a total of two patents to his name, Heubes has focused on advancements that improve the efficacy of antibiotic treatments.
Latest Patents
Heubes' latest patents include intricate compounds such as the crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1'-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester. This solid DMSO solvate is recognized for its potential as a useful intermediate in the manufacture of broad-spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril. These advancements reflect Heubes' dedication to enhancing medical treatments for various infections.
Career Highlights
Throughout his career at Basilea Pharmaceutica AG, Heubes has developed a strong reputation for his innovative ideas and research in medicinal chemistry. His pioneering work on antibiotic formulations and structures has paved the way for more effective treatment options in the pharmaceutical market.
Collaborations
Markus Heubes has collaborated with industry professionals such as Walter Cabri and Davide Longoni, further amplifying the impact of his research. Together, they have contributed to significant advancements in the field of antibiotics, demonstrating the power of teamwork in innovation.
Conclusion
Markus Heubes stands out as an influential inventor in the pharmaceutical industry. His commitment to developing effective antibiotic solutions through innovative compounds exemplifies the importance of research and collaboration in driving progress. As Heubes continues his work with Basilea Pharmaceutica AG, the medical field can anticipate further advancements stemming from his creative and precise inventions.